Faster, cheaper and more accurate is an understatement. We’re helping the world discover new medicine at a faster pace.
We are constantly publishing our results in peer-reviewed journals. Please find the works from our team and collaborators below.
We are excited to announce a new research publication showcasing the capabilities of our AKITA microfluidic platform. Authored by Tuan Nguyen et al., the paper titled "Highly Scalable and Standardized Organ-on-Chip Platform with TEER for Biological Barrier Modeling" highlights the potential of AKITA in advancing vascularized biological barrier research.In collaboration with esteemed partners including Organo-Therapeutics, the University of Kuopio, and the screening facility of Helsinki University, our platform has proven to be a key tool for researchers, pharmaceutical innovators, and investors alike. The study affirms AKITA's versatility, demonstrating its effectiveness in automation, organoid culture, and organotypic slice culture.
The laboratory of Prof. Ozlem Yesil‑Celiktas we presented a meticulous exploration of neural/glial cell differentiation from single-origin hiPSCs—a venture that unveils a sophisticated humanized neural tissue-on-chip model, supported by the blood-brain barrier (BBB). Their extracellular vesicles derived from bone marrow mesenchymal stem cells successfully crossed the blood brain barrier, and attenuated neuro-inflammation. This scientific promises a deeper understanding of cellular dynamics and presents avenues for innovative approaches in neuroinflammation research: "Differentiation of Neurons, Astrocytes, Oligodendrocytes and Microglia From Human Induced Pluripotent Stem Cells to Form Neural Tissue‑On‑Chip: A Neuroinflammation Model to Evaluate the Therapeutic Potential of Extracellular Vesicles Derived from Mesenchymal Stem Cells”
Our lumen-on-chip platform was used in the recent publication in Oncogene by Professor Aki Manninen from Disease Networks at University of Oulu: "Disassembly of hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin into focal adhesions" . With Professor Manninen we demonstrated that simultaneous loss of PTEN and hemidesmosomes induced several tumorigenic properties including proliferation, migration, resistance to anoikis, apoptosis, and drug treatment in vitro, and increased metastatic capacity in vivo by using an extensive CRISPR/Cas9-mediated genetic engineering approaches in different prostate cancer cell lines combined with in vivo tumorigenesis studies in mice, bone marrow-on-chip assays and bioinformatics, as well as histological analysis of prostate cancer patient cohorts. The studies showed that these effects were driven by activation of EGFR/PI3K/Akt and FAK/Src-pathways and were abolished by plectin downregulation. Therefore, dual loss of PTEN and hemidesmosomes may have diagnostic value helping to stratify prostate cancer patients with a high risk for development of aggressive disease and highlight plectin as a potential therapeutic target in prostate cancer.
Data published in MDPI publication "Functional Characterization of Mechanosensitive Piezo1 Channels in Trigeminal and Somatic Nerves in a Neuron-on-Chip Model” by Nikita et al at A. I. Virtanen Institute for Molecular Sciences has shown that turbulence free microfluidic neuron-on-chip clearly differentiates trigeminal versus dorsal root ganglion neural mechanosensitivity. Finnadvance’s precision microfluidic chip fabrication demonstrated reproducibility of the results.
Here you can find AKITA posters and more information about our and our collaborator's scientific work.
Want to understand how AKITA platform could help you achieve the scientific milestones faster with higher confidence? Below you can download our scientific protocols.
Discover the capacities of the AKITA platform and how it can help you in your research.
Contact us at contact@akita.bio to gain access to the multiple protocols for organ-on-chip generation and the numerous readouts available.
Talk to our team of experts and we'll help you find a solution that will supercharge your research.
Talk to sales
